Information

  • Nov 14, 2024

Oil settles slightly higher, investors focus on steep draw in fuel stocks

Brent crude futures settled 28 cents, or 0.4% higher at $72.56 a barrel, while U.S. West Texas Intermediate crude futures rose 27 cents, or 0.4% at $68.70. Both benchmarks had briefly dipped into negative territory during the trading session. Brent was on track to lose about 1.7% for the week, while WTI was set to end the week over 2% lower due to a stronger U.S. dollar and worries about rising supply amid slow demand growth.

  • Nov 14, 2024

China Copper Buyers Cut Annual Contracts With Market in Flux

(Bloomberg) -- China’s copper importers are reining in the amount of tonnage they buy through annual supply negotiations, once a bellwether for the global metal market, and opting for spot supplies instead.Most Read from BloombergUnder Trump, Prepare for New US Transportation PrioritiesZimbabwe City of 700,000 at Risk of Running Dry by Year-EndNYC Congestion Pricing Plan With $9 Toll to Start in JanuarySaudi Neom Gets $3 Billion Loan Guarantee From Italy Export Credit Agency SaceThe Urban-Rural

  • Nov 14, 2024

Banxico Cuts for Third Meeting as Core Inflation Slows

(Bloomberg) -- Mexico delivered a third straight interest rate cut as a key measure of underlying inflation retreats and concerns mount over the slowdown in Latin America’s No. 2 economy.Most Read from BloombergUnder Trump, Prepare for New US Transportation PrioritiesZimbabwe City of 700,000 at Risk of Running Dry by Year-EndNYC Congestion Pricing Plan With $9 Toll to Start in JanuarySaudi Neom Gets $3 Billion Loan Guarantee From Italy Export Credit Agency SaceThe Urban-Rural Divide Over Highway

  • Nov 14, 2024

GSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why

On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase 3 trial of Blenrep (belantamab mafodotin) in combination with bortezomib plus dexamethasone (BorDex) as a second-line or later treatment for relapsed or refractory multiple myeloma. The trial met the key secondary endpoint of overall survival (OS), showing that belantamab mafodotin when combined with BorDex significantly reduced the risk of death versus standard of care da

  • Nov 14, 2024

What Is Plug Power's Future? Analysts Warn Of Cash Crunch And Slow Hydrogen Market Growth

Analysts revised the price target or estimates on Plug Power, Inc. (NASDAQ:PLUG) after the company reported weak third-quarter results and provided FY25 guidance. On Wednesday, Plug provided its financial outlook for 2025, projecting revenue between $850 million and $950 million (street view: $1.185 billion). Looking further ahead, the company aims for a target revenue of approximately $3.75 billion by 2030. Also this week, Plug Power reported third-quarter revenue of $173.73 million, which miss

Popular Post